InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,312.80
(
0.08%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
74.09
(
0.47%
)
Bitcoin
63,288.55
(
-0.08%
)
Post# of 253199
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

willyw

Send PM Follow Ignore
Followers 14
Posts 734
Boards Moderated 0
Alias Born 12/09/2013

willyw

Re: DewDiligence post# 213184

Friday, 08/18/2017 12:42:43 PM

Friday, August 18, 2017 12:42:43 PM

Post# of 253199
Yes, I saw. We are also seeing how quickly things are getting approved AND approvals from payors/insurance companies/agencies.

I rather expect Japan to also follow suit.
I've seen comments on this board remarking that China is streamlining approvals.

I also wonder if it will be true that relatively new therapies may also fade from usage?
Incivek, Victrelis, simeprevir had relatively short shelf lives.

What lies in store for Daclatasvir? Zepatier?

What are the implications for HCV drug therapies in trials? (JNJ, MRK)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up